Cost, coverage, and comparative effectiveness research: The critical issues for oncology

Journal of Clinical Oncology

Volumn 30, Issue 34, 2012, Pages 4275-4281

  Pearson, Steven D ^a,b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER RESEARCH; CANCER THERAPY; COMPARATIVE EFFECTIVENESS; COST; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH INSURANCE; HEALTH SERVICE; HUMAN; PRIORITY JOURNAL; REVIEW; UNITED STATES;

COMPARATIVE EFFECTIVENESS RESEARCH; COST-BENEFIT ANALYSIS; HEALTH CARE COSTS; HUMANS; INSURANCE COVERAGE; MEDICAL ONCOLOGY;

EID: 84870702055     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.42.6601     Document Type: Review

References (35)

1. Conway PH, Clancy C: Comparative-effectiveness research: Implications of the Federal Coordinating Council's Report. N Engl J Med 361:328-330, 2009
2. Pearson S: From better evidence to better care: Using comparative effectiveness research to guide practice and policy, in Brookings Institution: Implementing Comparative Effectiveness Research: Priorities, Methods and Impact. Washington, DC, Brookings Institution, 2009, pp 55-82
3. Orszag PR: Health care and the budget: Issues and challenges for reform - Statement before the Committee on the Budget, US Senate. Washington, DC, Congressional Budget Office, 2007
4. Neumann PJ, Palmer JA, Nadler E, et al: Cancer therapy costs influence treatment: A national survey of oncologists. Health Aff (Millwood) 29:196-202, 2010
5. Fojo T, Grady C: How much is life worth: Cetuximab, non-small cell lung cancer, and the $440 billion question. J Natl Cancer Inst 101:1044-1048, 2009
6. Sullivan R, Peppercorn J, Sikora K, et al: Delivering affordable cancer care in high-income countries. Lancet Oncol 12:933-980, 2011
7. Wilensky GR: Developing a center for comparative effectiveness information. Health Aff (Millwood) 25:w572-w585, 2006
8. American Academy of Family Physicians, American College of Physicians, Society of General Internal Medicine: Letter to Congress, July 13, 2009. http://www.acponline.org/advocacy/where-we-stand/access/cer-draft09.pdf
9. Chalkidou K, Tunis S, Lopert R, et al: Comparative effectiveness research and evidence-based health policy: Experience from four countries. Milbank Q 87:339-367, 2009
10. Low E: Many new cancer drugs in the United Kingdom are facing negative NICE rulings. J Clin Oncol 25:2635-2636, 2007
11. McCaughey B: GovernmentCare's assault on seniors. http://online.wsj.com/ article/SB10001424052970203517304574303903498159292.html
12. Tunis SR, Pearson SD: Coverage options for promising technologies: Medicare's 'coverage with evidence development'. Health Aff (Millwood) 25:1218-1230, 2006 (Pubitemid 44497620)
13. Garber AM: A menu without prices. Ann Intern Med 148:964-966, 2008
14. American College of Physicians: Information on cost-effectiveness: An essential product of a national comparative effectiveness program. Ann Intern Med 148:956-961, 2008
15. Wilensky GR: Cost-effectiveness information: Yes, it's important, but keep it separate, please! Ann Intern Med 148:967-968, 2008
16. Pitts PJ: Comparative effectiveness: Government's way to convert patients into cost centers? http://cmpi.org/in-the-news/in-the-news/comparative- effectiveness-governments-way-to-convert-patients-into-cost-centers
17. Partnership to Improve Patient Care: News article on PCOR definition features AMA, PIPC. http://www.improvepatientcare.org/blog/news-article-pcor- definition-features-ama-pipc
18. Inside Health Policy: PCORI head vows not to do cost-effectiveness studies, but notes gray areas. http://insidehealthpolicy.com/Inside-Health- General/Public-Content/pcori-head-vows-not-to-do-cost-effectiveness-studies-but- notes-gray-areas/menu-id-869.html
19. Neumann PJ: What we talk about when we talk about health care costs. N Engl J Med 366:585-586, 2012
20. Mays N: Knowledge is not always power. BMJ 341:c4217, 2010
21. Pfister DG: Off-label use of oncology drugs: The need for more data and then some. J Clin Oncol 30:584-586, 2012
22. Mullins CD, Montgomery R, Abernethy AP, et al: Recommendations for clinical trials of off-label drugs used to treat advanced-stage cancer. J Clin Oncol 30:661-666, 2012
23. Bach PB: Limits on Medicare's ability to control rising spending on cancer drugs. N Engl J Med 360:626-633, 2009
24. Abernethy AP, Raman G, Balk EM, et al: Systematic review: Reliability of compendia methods for off-label oncology indications. Ann Intern Med 150:336-343, 2009
25. Lee TH, Emanuel EJ: Tier 4 drugs and the fraying of the social compact. N Engl J Med 359:333-334, 2008
26. National Comprehensive Cancer Network: Guidelines for patients: Non-small cell lung cancer. http://www.nccn.org/patients/patient-guidelines/nscl/index. html#/24/
27. Tunis SR, Pearson SD: US moves to improve health decisions. BMJ 341:c3615, 2010
28. Dreyer NA, Tunis SR, Berger M, et al: Why observational studies should be among the tools used in comparative effectiveness research. Health Aff (Millwood) 29:1818-1825, 2010
29. Pearson SD, Miller FG, Emanuel EJ: Medicare's requirement for research participation as a condition of coverage: Is it ethical? JAMA 296:988-991, 2006 (Pubitemid 44285376)
30. ThePharmaLetter: German pharma criticizes new AMNOG vetting procedure. http://www.thepharmaletter.com/file/111771/german-pharma-criticizes-new- amnogvetting-procedure.html
31. Carlson JJ, Sullivan SD, Garrison LP, et al: Linking payment to health outcomes: A taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers. Health Policy 96:179-190, 2010
32. Carlson JJ, Garrison LP Jr, Sullivan SD: Paying for outcomes: Innovative coverage and reimbursement schemes for pharmaceuticals. J Manag Care Pharm 15:683-687, 2009
33. Pearson SD, Bach PB: How Medicare could use comparative effectiveness research in deciding on new coverage and reimbursement. Health Aff (Millwood) 29:1796-1804, 2010
34. Meropol NJ, Schrag D, Smith TJ, et al: American Society of Clinical Oncology guidance statement: The cost of cancer care. J Clin Oncol 27:3868-3874, 2009
35. Basch E, Somerfield MR, Partridge A, et al: Should cost and comparative value of treatments be considered in clinical practice guidelines? J Oncol Pract 7:398-401, 2011